Unveiling 4 Analyst Insights On AnaptysBio
Portfolio Pulse from Benzinga Insights
AnaptysBio (NASDAQ:ANAB) has received mixed ratings from 4 analysts in the past three months, with a shift towards a neutral stance in the last 30 days. The average 12-month price target has been raised to $53.25 from $30.00, indicating a 77.5% increase. Analysts from JP Morgan, BTIG, Stifel, and Piper Sandler have adjusted their ratings and price targets, reflecting changing market conditions and AnaptysBio's performance. The company, focusing on antibody product candidates for inflammation and immuno-oncology, shows strong market confidence with a significant market capitalization and a solid revenue growth rate of 32.27% as of December 31, 2023.
April 01, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AnaptysBio has seen a notable increase in its average 12-month price target to $53.25, reflecting a positive outlook from analysts despite mixed ratings. The company's significant market capitalization and solid revenue growth rate of 32.27% as of December 31, 2023, underscore its strong market presence and potential for growth.
The increase in the average 12-month price target for AnaptysBio, along with its solid revenue growth and significant market capitalization, suggests a positive outlook from analysts. This could lead to increased investor confidence and potential short-term price appreciation.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100